澳洋順昌(002245.SZ):吳建勇持股比例被動稀釋至5%以下
格隆匯2月19日丨澳洋順昌(002245.SZ)公佈,2020年2月,澳洋順昌因發生可轉債轉股事項,總股本增加1186股,由981,311,778股變為981,312,964股,信息披露義務人吳建勇持股比例由5%被動稀釋至4.999994%。
截止信息披露日,信息披露義務人吳建勇持有澳洋順昌股份無限售流通股4906.56萬股,所持股份為根據吳建勇與澳洋集團有限公司於2019年9月16日簽訂的《股份轉讓協議》所取得,所持股份無質押或凍結。吳建勇先生已按規定編制了《簡式權益變動報告書》並於2019年9月17日披露。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.